Form 4: Myriad Genetics Executive Dale Muzzey Reports Stock Transactions

Dale Muzzey, Chief Scientific Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Summary

• On March 22 and 24, 2025, Dale Muzzey, Chief Scientific Officer of Myriad Genetics, had shares of common stock withheld by the company to cover tax obligations.
• These withholdings were related to the vesting of both restricted stock units and performance-based restricted stock units.
• The price per share for the withholdings on March 22, 2025 was $10.01.
• The price per share for the withholdings on March 24, 2025 was $9.98.
• Following these transactions, Muzzey directly owns 171,541 shares of Myriad Genetics common stock.

Sentiment

Score: 5

Explanation: This is a neutral event, reflecting routine tax-related stock transactions by an executive. It doesn't inherently signal positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the US equity market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to tax obligations and do not represent a significant change in the executive's overall holdings.

Key Dates

Keywords

Form 4, Myriad Genetics, Stock Transactions, Dale Muzzey, Insider Trading, Tax Withholding, Restricted Stock Units, Performance Based Restricted Stock Units